Link Found Between Common Sexual Infection and Risk of Aggressive Prostate Cancer
September 12, 2009 - Boston, MA - A new study from Harvard School of Public Health (HSPH) and Brigham and Women's Hospital researchers
has found a strong association between the common sexually transmitted infection, Trichomonas vaginalis, and risk of advanced and lethal prostate cancer in men.
The study appears online on September 9, 2009, on the Journal of the National Cancer Institute website and will appear in a later print edition.
"Prostate cancer is the most common cancer among men in western countries, and the second leading cause of cancer-specific mortality.
Identifying modifiable risk factors for the lethal form of prostate cancer offers the greatest opportunity to reduce suffering from
this disease," said Jennifer Stark, an HSPH researcher and lead author of the study.
One potential risk factor is inflammation, which appears to play an important role in the development and progression of prostate cancer,
but the source of inflammation of the prostate is not clear. Trichomonas vaginalis, which infects an estimated 174 million people globally
each year and is the most common non-viral sexually transmitted infection, can infect the prostate and could be a source of inflammation.
With respect to prostate cancer prevention, it is noteworthy that up to three-quarters of men infected with Trichomonas vaginalis
may not realize they are infected, since they may not have any symptoms.
A previous study had found an association between risk of prostate cancer and Trichomonas vaginalis infection, but was not
large enough to determine if there was a link between the infection and advanced and lethal disease.
In the present study, the researchers analyzed blood samples from 673 men with prostate cancer who were participants in the
Physicians' Health Study and compared infection status based on antibody levels to 673 control subjects who were not diagnosed
with prostate cancer. The blood samples were collected in 1982, on average a decade before cancer diagnosis.
The results showed that Trichomonas vaginalis infection was associated with a more than two-fold increase in the risk of
prostate cancer that was advanced stage at diagnosis, and a nearly three-fold increase in prostate cancer that would result in death.
"The fact that we found a strong association between serologic evidence of infection with Trichomonas vaginalis, a potentially modifiable
risk factor, and risk of advanced and lethal disease represents a step forward in prostate cancer, especially given that so few risk
factors for aggressive prostate cancer have been identified," said Lorelei Mucci, assistant professor in the department of epidemiology at HSPH and senior author of the study.
The authors note that further research needs to be done to confirm the findings. If confirmed, the findings from the large-scale, prospective study
would identify infections as one of the few known modifiable factors for aggressive prostate cancer. Moreover, since the infection is easily treated with
an inexpensive antibiotic regimen, the results from the study suggest that prevention or early treatment of Trichomonas vaginalis infection could be a target for prostate cancer prevention.
Support for this study was provided by the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Harvard University Milton Fund,
the Dana-Farber/Harvard Cancer Center Prostate SPORE, and the Prostate Cancer Foundation.
"Prospective Study of Trichomonas vaginalis Infection and Prostate Cancer Incidence and Mortality: Physicians' Health Study,"
Jennifer R. Stark , Gregory Judson, John F. Alderete, Vasanthakrishna Mundodi, Ashwini S. Kucknoor, Edward L. Giovannucci, Elizabeth A. Platz, Siobhan Sutcliffe,
Katja Fall, Tobias Kurth, Jing Ma, Meir J. Stampfer, Lorelei A. Mucci, Journal of the National Cancer Institute, online September 9, 2009
For more information:
Todd Datz
617-432-3952
tdatz@hsph.harvard.edu
Visit the HSPH website for the latest news, press releases and multimedia offerings.
###
Harvard School of Public Health is dedicated to advancing the public's health through learning, discovery, and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit http://www.hsph.harvard.edu.
|
